QUEST informs readers of the latest advances in urologic prostate cancer research, especially detection, prevention, and treatment.
The news that former President Joe Biden has been diagnosed with a highly aggressive form of prostate cancer presents an opportunity to examine critical information that could help thousands of men avoid this life-threatening situation. Biden was diagnosed after he…
Screening for prostate cancer is controversial, but it shouldn’t be. In the U.S., prostate cancer is the most common non-skin cancer and the second-leading cause of cancer death in men, with an estimated 313,780 new cases being diagnosed in 2025,…
Because PSA screening has false positives, enhancements have been sought to increase the specificity of PSA testing. PSA Velocity (PSAV) correlates with both prostate cancer risk and aggressiveness. PSAV Risk Count quantifies the persistence of PSA increases over time,…
There are now many current treatment options for men with LUTS (lower urinary tract symptoms) from BPH (benign prostatichyperplasia). The first and simplest step is oral alpha-blocker medications. Alpha-blockers work by relaxing the musclesin the prostate and the bladder…
The American Cancer Society annually estimates the number of new cancer cases and deaths in the United States. It compiles data on cancer occurrence and outcomes. In 2025, over two million cancer cases and six hundred thousand cancer deaths are…
This large U.S.-based cohort study examined how county-level prostate-specific antigen (PSA) screening prevalence is associated with prostate cancer outcomes among over 814,000 men diagnosed between 2000 and 2015. Key findings include: Higher PSA screening prevalence was linked to: • Lower…
Multi-parametric MRI (mpMRI) is a key imaging tool for identifying clinically significant prostate cancer (defined as Gleason score≥7). However, its sensitivity and specificity are not perfect. Prostate cancer is highly heritable, and polygenic risk scores (PRS) based on germline…
This study looked at how well a newer type of imaging called PSMA-PET/CT works in detecting cancer in patients with high-risk, hormone-sensitive prostate cancer. These patients were similar to those included in the large EMBARK trial, which tested the drug…
This study focused on the often- overlooked health risks that men face when they carry inherited mutations in the BRCA1 and BRCA2 genes. While these genetic variants are commonly associated with a higher risk of breast and ovarian cancer in…
A long-term study involving over 19,000 men from Sweden and the U.S. investigated how genetic risk and lifestyle choices impact early prostate cancer deaths. The research, conducted from 1991 to 2019, found that men with higher genetic risk—determined by a…
"*" indicates required fields
